Light therapy occupies an unusual position: too well studied to dismiss, too unsettled to sell as proven. Getting that position right requires reading the actual reviews rather than the summaries of the summaries — so this piece walks through what the strongest available synthesis says, including the parts that complicate the story.
The Best Current Synthesis
The 2025 umbrella review of photobiomodulation, published in Systematic Reviews, sits at the top of the evidence hierarchy for this field. It analyzed 15 meta-analyses covering 204 randomized controlled trials and more than 9,000 participants across 35 health outcomes. Twelve outcomes showed statistically significant effects. Certainty of evidence ranged from very low to moderate. No outcome reached high certainty.
Moderate-certainty findings — the strongest tier available — included increased hair density in androgenetic alopecia, reduced disability in knee osteoarthritis, reduced fatigue in fibromyalgia, improvements in cognitive function, and pain reduction in burning mouth syndrome. That is a specific, unglamorous list, and specificity is what credibility looks like.
The Mechanism
Reviews of mechanisms and mitochondrial redox signalling describe absorption of red and near-infrared light within the mitochondrial respiratory chain, with downstream effects on cellular energy metabolism, reactive oxygen species signalling and pathways linked to inflammation and repair. One consequence of that model is clinically important and widely ignored: the dose response is biphasic. Too little light produces no measurable effect; too much can reduce or reverse it. "More" is not a protocol.
The Standardization Problem
Almost every limitation in the field traces back to one issue. Studies differ in wavelength, irradiance, total fluence, session length, treatment frequency, treatment duration and delivery method — and often report those parameters incompletely. Pooling such studies produces wide confidence intervals and low certainty ratings, not because light does nothing, but because the trials are not testing the same intervention.
This is visible across specific literatures. Sleep research is limited to a small number of trials: a systematic review and meta-analysis pooled five randomized trials with 240 participants, reporting improved sleep quality scores with limited precision. Cognitive research, summarized in a 2025 meta-analysis, flags protocol heterogeneity as its central caveat. A 2025 review of transcranial photobiomodulation raises the further question of how much light reaches cortical tissue at all.
Where Proprietary Systems Fit
Technologies such as The Light System™ operate inside this environment while extending beyond conventional PBM parameters. TLS reports laboratory measurements of bioelectrical activity and cellular conductivity rather than clinical endpoints, and states that it makes no medical claims about the technology. Its data belongs to a different category than the trials above — informative, manufacturer-reported, and not yet a substitute for independent clinical testing.
What Would Move the Field
Three things. Standardized dosimetry reporting, so trials become comparable. Larger, adequately powered, sham-controlled trials with pre-registered endpoints. And independent replication of proprietary findings by groups with no commercial interest in the result. When those arrive, certainty ratings will move in one direction or the other — and either outcome is progress.
On safety, a 2025 evidence-based consensus on the clinical application of photobiomodulation concluded that PBM is generally safe for adult patients, with individual precautions still applying.
Continue with the full Light System™ research guide, light therapy safety, or light for pain and physical recovery.
Educational information only. Not medical advice, and not an offer of The Light System™ as a service at Sanctuary Tulum.